A vaginal yeast infection is a fungal infection that causes irritation, discharge, and intense itchiness of the vagina and the vulva — the tissues at the vaginal opening. Vaginal fungi infection is also known as vaginal yeast infection, vulvovaginal candidiasis, candidal vaginitis or vaginal candidiasis, and it the second most common type of vaginal infection in the U.S., according the Centers for Disease Control and Prevention.
Rising incidence of vaginal fungi infections are driving vaginal fungi infections treatment market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), 2018, around 1.4 million outpatient visits occur for vaginal candidiasis every year in the U.S. Moreover, according to an article published in Multidisciplinary Digital Publishing Institute (MDPI) in February 2020, Vulvovaginal candidiasis (VVC) is the most prevalent human candidal infection and nearly 75% women across the globe are affected by it least once in their lifetime. Furthermore, according to the same source, around 8% women across the globe suffer from Recurrent Vulvovaginal Candidiasis (RVVC).
However, alternative therapies for vaginal fungi infections treatment can hinder the market growth. For instance, Nutrablast, a dedicated company in the dietary supplement and personal care offers Tea Tree Suppositories for vaginal fungi infections treatment. The product is natural tea tree oil to provide a balanced vaginal environment.
- This report provides in-depth analysis of the global vaginal fungi infections treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Vaginal Fungi Infections Treatment Market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, and SCYNEXIS, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global Vaginal Fungi Infections Treatment Market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vaginal fungi infections treatment market.
-
- Fluconazole
- Nystatin
- Flucytosine
- Others
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies.
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Pfizer Inc.
- Bausch Health Companies Inc
- ANI Pharmaceuticals, Inc.
- Hikma Pharmaceuticals Plc
- Lupin Limited, Mycovia Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Limited
- Unique Pharmaceuticals
- PEPTONIC medical AB
- Aurobindo Pharma Limited
- Reddy's Laboratories
- SCYNEXIS, Inc.
